DE69636531D1 - Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika - Google Patents

Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika

Info

Publication number: DE69636531D1
Authority: DE; Germany
Prior art keywords: oral; agent; target; bioavailability; enhancing
Prior art date: 1995-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69636531T

Other languages

English (en)

Other versions

DE69636531T2 (de

Inventor

Samuel Broder

Kenneth Duchin

Sami Selim

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ivax Research Holdings Inc

Original Assignee

Ivax Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-26

Filing date

1996-10-24

Publication date

2006-10-19

1996-02-29 Priority claimed from US08/608,776 external-priority patent/US5968972A/en

1996-10-24 Application filed by Ivax Research Inc filed Critical Ivax Research Inc

2006-10-19 Publication of DE69636531D1 publication Critical patent/DE69636531D1/de

2006-12-07 Application granted granted Critical

2006-12-07 Publication of DE69636531T2 publication Critical patent/DE69636531T2/de

2016-10-25 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title abstract 3
239000003814 drug Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003795 chemical substances by application Substances 0.000 abstract 12
239000002246 antineoplastic agent Substances 0.000 abstract 2
238000011260 co-administration Methods 0.000 abstract 2
230000002708 enhancing effect Effects 0.000 abstract 2
239000006186 oral dosage form Substances 0.000 abstract 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
GNGBSKIQPUCELM-YBAOVNABSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(e,2r)-2-methylhex-4-enyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29, Chemical compound CC[C@@H]1NC(=O)[C@H](C[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-YBAOVNABSA-N 0.000 abstract 1
ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
GNGBSKIQPUCELM-UHFFFAOYSA-N Cyclosporin F Natural products CCC1NC(=O)C(CC(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-UHFFFAOYSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
108010019594 cyclosporin D Proteins 0.000 abstract 1
108010019252 cyclosporin F Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960003668 docetaxel Drugs 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
229960005420 etoposide Drugs 0.000 abstract 1
229960004125 ketoconazole Drugs 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DE69636531T 1995-10-26 1996-10-24 Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika Expired - Fee Related DE69636531T2 (de)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US707195P	1995-10-26	1995-10-26
US7071P		1995-10-26
US608776		1996-02-29
US08/608,776 US5968972A (en)	1995-10-26	1996-02-29	Method for increasing the oral bioactivity of pharmaceutical agents
US733142		1996-10-16
US08/733,142 US6245805B1 (en)	1995-10-26	1996-10-16	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
PCT/IB1996/001485 WO1997015269A2 (en)	1995-10-26	1996-10-24	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Publications (2)

Publication Number	Publication Date
DE69636531D1 true DE69636531D1 (de)	2006-10-19
DE69636531T2 DE69636531T2 (de)	2006-12-07

Family

ID=27358262

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE0794794T Pending DE794794T1 (de)	1995-10-26	1996-10-24	Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
DE69636531T Expired - Fee Related DE69636531T2 (de)	1995-10-26	1996-10-24	Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE0794794T Pending DE794794T1 (de)	1995-10-26	1996-10-24	Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika

Country Status (22)

Country	Link
US (6)	US6245805B1 (de)
EP (1)	EP0794794B1 (de)
JP (1)	JP3361102B2 (de)
CN (2)	CN100335123C (de)
AT (1)	ATE311903T1 (de)
AU (1)	AU698142B2 (de)
BR (1)	BR9607066A (de)
CA (1)	CA2205534A1 (de)
CZ (1)	CZ202897A3 (de)
DE (2)	DE794794T1 (de)
DK (1)	DK0794794T3 (de)
ES (1)	ES2109899T3 (de)
HK (1)	HK1001960A1 (de)
HU (1)	HUP9900457A3 (de)
IL (1)	IL121160A0 (de)
MX (1)	MX9704629A (de)
NO (1)	NO321091B1 (de)
NZ (1)	NZ324801A (de)
PL (2)	PL188281B1 (de)
RU (1)	RU2217135C2 (de)
SK (1)	SK85997A3 (de)
WO (1)	WO1997015269A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5439686A (en) *	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6395770B1 (en) *	1995-10-26	2002-05-28	Baker Norton Pharmaceuticals, Inc.	Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) *	1995-10-26	2005-11-15	Baker Norton Pharmaceuticals, Inc.	Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1550231A (zh) *	1997-05-27	2004-12-01	�Ϳˡ�ŵ��ҩ��޹�˾	给予病人口服紫杉烷类药物的方法和组合物
US8853260B2 (en)	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB9718903D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU9785698A (en) *	1997-10-02	1999-04-27	Microcide Pharmaceuticals, Inc.	Fungal efflux pump inhibitors
BR9912501A (pt) *	1998-06-29	2001-05-02	Los Angeles Childrens Hospital	Tratamento de distúrbios hiperproliferativos
DE60030283T2 (de)	1999-05-17	2007-09-20	Cancer Research Ventures Ltd.	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
EP1479382A1 (de) *	1999-06-18	2004-11-24	IVAX Research, Inc.	Taxane enthaltende orale Pharmazeutische Zusammensetzungen sowie Behandlungsverfahren unter deren Verwendung
GB9920548D0 (en) *	1999-08-31	1999-11-03	Rhone Poulenc Rorer Sa	Treatment of hepatocellular carcinoma
US20020147197A1 (en) *	1999-10-08	2002-10-10	Newman Michael J.	Methods and compositions for enhancing pharmaceutical treatments
EP1225956A1 (de) *	1999-10-27	2002-07-31	Baker Norton Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur oralen verabreichung von taxanen an menschlichen patienten
CA2367661A1 (en) *	2000-02-02	2001-08-09	Robert A. Holton	Taxane formulations having improved solubility
US6750246B1 (en)	2000-02-03	2004-06-15	Bristol-Myers Squibb Company	C-4 carbonate taxanes
US20030158097A1 (en) *	2000-03-02	2003-08-21	Norifumi Tanida	P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
US6362217B2 (en)	2000-03-17	2002-03-26	Bristol-Myers Squibb Company	Taxane anticancer agents
US20030144312A1 (en) *	2001-10-30	2003-07-31	Schoenhard Grant L.	Inhibitors of ABC drug transporters in multidrug resistant cancer cells
AU2002363523A1 (en) *	2001-11-07	2003-05-19	Pharmacia Corporation	Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
KR20040066921A (ko) *	2001-12-20	2004-07-27	브리스톨-마이어스스퀴브컴파니	생체이용률이 향상된 경구 활성 탁산 유도체의 제약조성물
JP2006514698A (ja) *	2002-10-30	2006-05-11	スフェリックス，インコーポレイテッド	ナノ粒子生物活性物質
US20050113324A1 (en) *	2003-01-15	2005-05-26	Bondarev Igor E.	Modulation of line-1 reverse transcriptase
US20060014677A1 (en) *	2004-07-19	2006-01-19	Isotechnika International Inc.	Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20070087977A1 (en) *	2004-11-16	2007-04-19	Wendye Robbins	Methods and compositions for treating pain
GB2423928B (en) *	2004-11-16	2008-04-09	Efflux Technology Inc	Methods and compositions for treating pain
AU2006304143A1 (en) *	2005-10-14	2007-04-26	Allergan, Inc.	Prevention and treatment of drug-associated ocular side effects with a cyclosporin
US7745400B2 (en) *	2005-10-14	2010-06-29	Gregg Feinerman	Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
MX2009013663A (es) *	2007-06-22	2010-01-27	Scidose Llc	Formulacion solubilizada de docetaxel sin tween 80.
US20090111736A1 (en) *	2007-10-29	2009-04-30	Sri International	Orally-Absorbed Solid Dose Formulation for Vancomycin
CN101559059B (zh) *	2008-04-16	2012-12-05	北京万全阳光医学技术有限公司	一种含有盐酸阿米洛利的药物组合物及其制备方法
US20090318561A1 (en) *	2008-06-23	2009-12-24	Mutual Pharmaceutical Company, Inc.	Colchicine products, method of manufacture, and methods of use
US20110207660A1 (en) *	2008-08-07	2011-08-25	Schering Corporation	Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US7820681B1 (en)	2009-01-14	2010-10-26	Mutual Pharmaceutical Company, Inc.	Methods for concomitant administration of colchicine and a second active agent
US20110046228A1 (en) *	2009-08-20	2011-02-24	Mutual Pharmaceutical Company, Inc.	Methods for administration of colchicine with grapefruit juice
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
US20110092579A1 (en) *	2009-10-19	2011-04-21	Scidose Llc	Solubilized formulation of docetaxel
US8541465B2 (en) *	2009-10-19	2013-09-24	Scidose, Llc	Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en)	2009-10-19	2014-12-16	Scidose Llc	Docetaxel formulations with lipoic acid
US20110142889A1 (en) *	2009-12-16	2011-06-16	Nod Pharmaceuticals, Inc.	Compositions and methods for oral drug delivery
CN102970990A (zh)	2010-05-03	2013-03-13	帝国制药美国公司	非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
US20120295932A1 (en) *	2011-05-17	2012-11-22	Western Connecticut Health Network, Inc.	Method for the treatment of cancer
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
TWI752750B (zh)	2015-09-30	2022-01-11	香港商慧源香港創新有限公司	口服紫杉烷組合物及方法
CN107843966B (zh)	2016-09-18	2021-05-04	中芯国际集成电路制造(上海)有限公司	用于装配微透镜阵列组件的方法和***
CN106822085B (zh) *	2016-12-17	2020-03-17	浙江省人民医院	表达trail的溶瘤腺病毒联合槲皮素在抑制肝癌癌细胞增殖中的用途
SG11202105221XA (en) *	2018-11-21	2021-06-29	Elevar Therapeutics Inc	Pharmaceutical methods

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5118493A (en)	1986-05-02	1992-06-02	Brigham And Women's Hospital	Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
ATE95193T1 (de)	1987-06-17	1993-10-15	Sandoz Ag	Cyclosporine und deren benutzung als arzneimittel.
CA1340821C (en)	1988-10-06	1999-11-16	Nobuyuki Fukazawa	Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
JP2525478B2 (ja)	1989-03-01	1996-08-21	帝人株式会社	安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
US4960790A (en) *	1989-03-09	1990-10-02	University Of Kansas	Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5114951A (en)	1989-04-11	1992-05-19	Burroughs Wellcome Company	Agents for combating multiple drug resistance
US5208238A (en)	1989-06-19	1993-05-04	Burroughs Wellcome Company	Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB8914040D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914062D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914061D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914060D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8926715D0 (en)	1989-11-28	1990-01-17	Haessle Ab	Improvements relating to the administration of pharmaceutical agents
AU665341B2 (en)	1990-12-18	1996-01-04	Wellcome Foundation Limited, The	Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2783680B2 (ja)	1991-01-11	1998-08-06	ラボラトワール、グラクソ、ソシエテ、アノニム	アクリジン誘導体
US5166207A (en)	1991-06-17	1992-11-24	Neurotherapeutics, Inc.	Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
FR2678833B1 (fr) *	1991-07-08	1995-04-07	Rhone Poulenc Rorer Sa	Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5750561A (en)	1991-07-08	1998-05-12	Rhone-Poulenc Rorer, S.A.	Compositions containing taxane derivatives
ES2224200T3 (es)	1992-11-27	2005-03-01	Mayne Pharma (Usa) Inc.	Composicion inyectable estable de paclitaxel.
FR2698543B1 (fr)	1992-12-02	1994-12-30	Rhone Poulenc Rorer Sa	Nouvelles compositions à base de taxoides.
US5646176A (en)	1992-12-24	1997-07-08	Bristol-Myers Squibb Company	Phosphonooxymethyl ethers of taxane derivatives
US6096331A (en)	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US5387685A (en)	1993-07-16	1995-02-07	American Cyanamid Co	MDR reversal agents
CA2129288C (en) *	1993-08-17	2000-05-16	Jerzy Golik	Phosphonooxymethyl esters of taxane derivatives
TW406020B (en) *	1993-09-29	2000-09-21	Bristol Myers Squibb Co	Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5610173A (en) *	1994-01-07	1997-03-11	Sugen, Inc.	Formulations for lipophilic compounds
US5567592A (en)	1994-02-02	1996-10-22	Regents Of The University Of California	Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5565478A (en) *	1994-03-14	1996-10-15	The United States Of America As Represented By The Department Of Health & Human Services	Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr)	1994-04-25	1996-05-24	Rhone Poulenc Rorer Sa	Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) *	1994-07-19	1997-04-01	Hemagen/Pfc	Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5681846A (en) *	1995-03-17	1997-10-28	Board Of Regents, The University Of Texas System	Extended stability formulations for paclitaxel
US5665386A (en) *	1995-06-07	1997-09-09	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) *	1995-06-07	1998-02-10	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
GB9514878D0 (en) *	1995-07-20	1995-09-20	Danbiosyst Uk	Vitamin E as a solubilizer for drugs contained in lipid vehicles
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) *	1995-10-26	2002-05-28	Baker Norton Pharmaceuticals, Inc.	Method and compositions for administering taxanes orally to human patients
US5968972A (en) *	1995-10-26	1999-10-19	Baker Norton Pharmaceuticals, Inc.	Method for increasing the oral bioactivity of pharmaceutical agents
WO1997027855A1 (en)	1996-01-31	1997-08-07	Bristol-Myers Squibb Company	A method of making pharmaceutically active taxanes orally bioavailable
US5877205A (en) *	1996-06-28	1999-03-02	Board Of Regents, The University Of Texas System	Parenteral paclitaxel in a stable non-toxic formulation
US6458373B1 (en) *	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
IL131217A0 (en) *	1998-03-10	2001-01-28	Napro Biotherapeutics Inc	Novel methods and compositions for delivery of taxanes
US6136846A (en) *	1999-10-25	2000-10-24	Supergen, Inc.	Formulation for paclitaxel

1996
- 1996-10-16 US US08/733,142 patent/US6245805B1/en not_active Expired - Fee Related
- 1996-10-24 CN CNB031458033A patent/CN100335123C/zh not_active Expired - Fee Related
- 1996-10-24 ES ES96943268T patent/ES2109899T3/es not_active Expired - Lifetime
- 1996-10-24 CN CN96191685A patent/CN1119146C/zh not_active Expired - Fee Related
- 1996-10-24 JP JP51644997A patent/JP3361102B2/ja not_active Expired - Fee Related
- 1996-10-24 DE DE0794794T patent/DE794794T1/de active Pending
- 1996-10-24 AU AU12056/97A patent/AU698142B2/en not_active Ceased
- 1996-10-24 BR BR9607066-8A patent/BR9607066A/pt not_active Application Discontinuation
- 1996-10-24 DE DE69636531T patent/DE69636531T2/de not_active Expired - Fee Related
- 1996-10-24 MX MX9704629A patent/MX9704629A/es not_active IP Right Cessation
- 1996-10-24 SK SK859-97A patent/SK85997A3/sk unknown
- 1996-10-24 PL PL96321791A patent/PL188281B1/pl not_active IP Right Cessation
- 1996-10-24 CZ CZ972028A patent/CZ202897A3/cs unknown
- 1996-10-24 RU RU97112888/14A patent/RU2217135C2/ru not_active IP Right Cessation
- 1996-10-24 IL IL12116096A patent/IL121160A0/xx unknown
- 1996-10-24 DK DK96943268T patent/DK0794794T3/da active
- 1996-10-24 PL PL368566A patent/PL192544B1/pl unknown
- 1996-10-24 HU HU9900457A patent/HUP9900457A3/hu unknown
- 1996-10-24 CA CA002205534A patent/CA2205534A1/en not_active Abandoned
- 1996-10-24 NZ NZ324801A patent/NZ324801A/xx unknown
- 1996-10-24 AT AT96943268T patent/ATE311903T1/de not_active IP Right Cessation
- 1996-10-24 EP EP96943268A patent/EP0794794B1/de not_active Expired - Lifetime
- 1996-10-24 WO PCT/IB1996/001485 patent/WO1997015269A2/en active IP Right Grant
1997
- 1997-06-25 NO NO19972968A patent/NO321091B1/no unknown
1998
- 1998-02-11 HK HK98101042A patent/HK1001960A1/xx not_active IP Right Cessation
2001
- 2001-04-10 US US09/829,846 patent/US6610735B2/en not_active Expired - Fee Related
2002
- 2002-09-12 US US10/242,050 patent/US6818615B2/en not_active Expired - Fee Related
2004
- 2004-03-15 US US10/800,990 patent/US7041640B2/en not_active Expired - Fee Related
2005
- 2005-04-13 US US11/105,081 patent/US20050238634A1/en not_active Abandoned
2006
- 2006-08-14 US US11/503,607 patent/US20070060635A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE311903T1 (de)	2005-12-15
NO972968D0 (no)	1997-06-25
CN100335123C (zh)	2007-09-05
PL321791A1 (en)	1997-12-22
US20050238634A1 (en)	2005-10-27
CZ202897A3 (cs)	1998-03-18
CN1490048A (zh)	2004-04-21
JP3361102B2 (ja)	2003-01-07
NO321091B1 (no)	2006-03-13
PL192544B1 (pl)	2006-11-30
HUP9900457A3 (en)	2001-04-28
IL121160A0 (en)	1997-11-20
CA2205534A1 (en)	1997-05-01
US20030069301A1 (en)	2003-04-10
WO1997015269A3 (en)	1997-07-31
US20070060635A1 (en)	2007-03-15
US20040176439A1 (en)	2004-09-09
MX9704629A (es)	1997-09-30
US6610735B2 (en)	2003-08-26
EP0794794A4 (de)	2000-03-01
DE794794T1 (de)	1998-03-12
WO1997015269A2 (en)	1997-05-01
AU698142B2 (en)	1998-10-22
US6245805B1 (en)	2001-06-12
US7041640B2 (en)	2006-05-09
HUP9900457A2 (hu)	1999-06-28
DK0794794T3 (da)	2006-04-18
NZ324801A (en)	1999-05-28
CN1119146C (zh)	2003-08-27
EP0794794B1 (de)	2005-12-07
NO972968L (no)	1997-07-23
PL188281B1 (pl)	2005-01-31
ES2109899T1 (es)	1998-02-01
RU2217135C2 (ru)	2003-11-27
SK85997A3 (en)	1998-06-03
US20020058616A1 (en)	2002-05-16
JPH10509741A (ja)	1998-09-22
US6818615B2 (en)	2004-11-16
DE69636531T2 (de)	2006-12-07
CN1173817A (zh)	1998-02-18
EP0794794A1 (de)	1997-09-17
AU1205697A (en)	1997-05-15
HK1001960A1 (en)	1998-07-24
BR9607066A (pt)	2002-12-10
ES2109899T3 (es)	2006-05-01

Legal Events

Date	Code	Title	Description
2007-01-11	8364	No opposition during term of opposition
2009-08-20	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE69636531D1 (de)	2006-10-19	Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
BG101118A (en)	1998-04-30	Therapeutical compounds
ATE264671T1 (de)	2004-05-15	Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
DE69713526D1 (de)	2002-07-25	Lösliche prodrugs von paclitaxel
MXPA04000920A (es)	2004-04-02	Derivados de aminoisoxazol activos como inhibidores de la cinasa.
FI962735A0 (fi)	1996-07-03	2-hydroksi-5-fenylatsobensoehapon johdannaisten käyttö paksusuolen syövän kemialliseen ehkäisyyn ja kemoterapeuttisena aineena
DE60311567D1 (de)	2007-03-22	Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
HUP9902121A2 (hu)	1999-10-28	Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
DE3688114D1 (de)	1993-04-29	Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
CO5251419A1 (es)	2003-02-28	Composiciones nanoparticuladas de eplerenona
HUP0300836A2 (hu)	2003-08-28	Taxánokat tartalmazó szájon át beadható gyógyszerkészítmények és ezek alkalmazása
ATE292453T1 (de)	2005-04-15	Antivirale arznei
IS6558A (is)	2002-09-20	Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DE60030283D1 (de)	2006-10-05	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
HUP0003546A2 (hu)	2002-11-28	Kompozíciók taxánok orális adagolására embereknek
ATE311904T1 (de)	2005-12-15	Halbfester verabreichungsträger und arzneimittel
HK1079688A1 (en)	2006-04-13	Statin product for enhancing cognitive maintenance
RU94040886A (ru)	1996-09-20	Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
GEP20043377B (en)	2004-04-13	Pharmaceutical Complex
ATE293445T1 (de)	2005-05-15	Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
MD940244A (ro)	1996-01-31	Derivaţi noi ai tetrazolului, procedeu de obţinere a lor şi compoziţie farmaceutică pe baza lor